Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

gMG Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

5 recruiting trials for gMG. Eligibility criteria explained in plain English.

TrialFinderData lists 5 gMG clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 2 is the largest group at 33% (1 studies); the largest phase groups are Phase 2: 1, Phase 3: 1, Phase 4: 1.

Research is led by argenx (3), Alexion Pharmaceuticals, Inc. (2), among the most active sponsors registered for these trials.

The most frequently studied intervention is Efgartigimod IV (biological, 2 trials), followed by Empasiprubart IV, Gefurulimab.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
5
Total Trials
5
Recruiting Now
1
Phase 3 Trials
2
Sponsors

Track gMG trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT07294170

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in...

ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best...

Sponsor: argenxEnrolling: 7018 locations
RECRUITINGPhase 2NCT07284420

ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With...

This study is part of the ADAPT Forward platform study (NCT07294170). ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work...

Sponsor: argenxEnrolling: 7015 locations
RECRUITINGPhase 3NCT06607627

PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis

The primary objective of this study is to assess the pharmacokinetics and pharmacodynamics of gefurulimab in pediatric participants with AChR+ gMG for the duration of the study.

Sponsor: Alexion Pharmaceuticals, Inc.Enrolling: 1213 locations
RECRUITINGPhase 4NCT07221838

A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab

This is a prospective, multicenter single arm study designed to evaluate the effectiveness and safety of a predefined oral corticosteroids (OCS) tapering schedule to reduce OCS...

Sponsor: Alexion Pharmaceuticals, Inc.Enrolling: 7512 locations
RECRUITINGNCT07595653

A Study to Evaluate the Impact of Efgartigimod on Overall Disease Experience of People Suffering From Generalized...

This study aims to generate real world evidence (RWE) from Italian clinical practice on the impact of efgartigimod alfa in gMG patients encompassing clinical outcomes and patient...

Sponsor: argenxEnrolling: 10020 locations

Frequently Asked Questions

There are currently 5 clinical trials for gMG, with 5 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for gMG, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 1 Phase 3 trials for gMG, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.